File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Striatal dopamine synthesis capacity in twins discordant for schizophrenia

TitleStriatal dopamine synthesis capacity in twins discordant for schizophrenia
Authors
KeywordsDopamine
imaging
schizophrenia
twin study
Issue Date2011
PublisherCambridge University Press. The Journal's web site is located at http://journals.cambridge.org/action/displayJournal?jid=PSM
Citation
Psychological Medicine, 2011, v. 41 n. 11, p. 2331-2338 How to Cite?
AbstractBackground Elevated striatal dopamine synthesis capacity is thought to be fundamental to the pathophysiology of schizophrenia and has also been reported in people at risk of psychosis. It is therefore unclear if striatal hyperdopaminergia is a vulnerability marker for schizophrenia, or a state feature related to the psychosis itself. Relatives of patients with schizophrenia are themselves at increased risk of developing the condition. In this study we examined striatal dopamine synthesis capacity in both members of twin pairs discordant for schizophrenia. Method In vivo striatal dopamine synthesis capacity was examined using fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) scans in seven twin pairs discordant for schizophrenia and in a control sample of 10 healthy control twin pairs. Results Striatal 18F-DOPA uptake was not elevated in the unaffected co-twins of patients with schizophrenia (p=0.65) or indeed in the twins with schizophrenia (p=0.89) compared to the control group. Levels of psychotic symptoms were low in the patients with schizophrenia who were in general stable [mean (s.d.) Positive and Negative Syndrome Scale (PANSS) total=56.8 (25.5)] whereas the unaffected co-twins were largely asymptomatic. Conclusions Striatal dopamine synthesis capacity is not elevated in symptom-free individuals at genetic risk of schizophrenia, or in well-treated stable patients with chronic schizophrenia. These findings suggest that striatal hyperdopaminergia is not a vulnerability marker for schizophrenia. © 2011 Cambridge University Press.
Persistent Identifierhttp://hdl.handle.net/10722/141819
ISSN
2015 Impact Factor: 5.491
2015 SCImago Journal Rankings: 2.843
ISI Accession Number ID
Funding AgencyGrant Number
Wellcome Trust
Medical Research Council, Clinical Sciences Centre
Funding Information:

This study was funded by a Wellcome Trust Clinical Training Fellowship awarded to P. S. and by the Medical Research Council, Clinical Sciences Centre. We acknowledge infrastructure support from the National Institute for Health Research Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service Foundation Trust and the Institute of Psychiatry, King's College London.

References

 

DC FieldValueLanguage
dc.contributor.authorShotbolt, Pen_HK
dc.contributor.authorStokes, PRen_HK
dc.contributor.authorOwens, SFen_HK
dc.contributor.authorToulopoulou, Ten_HK
dc.contributor.authorPicchioni, MMen_HK
dc.contributor.authorBose, SKen_HK
dc.contributor.authorMurray, RMen_HK
dc.contributor.authorHowes, ODen_HK
dc.date.accessioned2011-09-27T03:02:34Z-
dc.date.available2011-09-27T03:02:34Z-
dc.date.issued2011en_HK
dc.identifier.citationPsychological Medicine, 2011, v. 41 n. 11, p. 2331-2338en_HK
dc.identifier.issn0033-2917en_HK
dc.identifier.urihttp://hdl.handle.net/10722/141819-
dc.description.abstractBackground Elevated striatal dopamine synthesis capacity is thought to be fundamental to the pathophysiology of schizophrenia and has also been reported in people at risk of psychosis. It is therefore unclear if striatal hyperdopaminergia is a vulnerability marker for schizophrenia, or a state feature related to the psychosis itself. Relatives of patients with schizophrenia are themselves at increased risk of developing the condition. In this study we examined striatal dopamine synthesis capacity in both members of twin pairs discordant for schizophrenia. Method In vivo striatal dopamine synthesis capacity was examined using fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) scans in seven twin pairs discordant for schizophrenia and in a control sample of 10 healthy control twin pairs. Results Striatal 18F-DOPA uptake was not elevated in the unaffected co-twins of patients with schizophrenia (p=0.65) or indeed in the twins with schizophrenia (p=0.89) compared to the control group. Levels of psychotic symptoms were low in the patients with schizophrenia who were in general stable [mean (s.d.) Positive and Negative Syndrome Scale (PANSS) total=56.8 (25.5)] whereas the unaffected co-twins were largely asymptomatic. Conclusions Striatal dopamine synthesis capacity is not elevated in symptom-free individuals at genetic risk of schizophrenia, or in well-treated stable patients with chronic schizophrenia. These findings suggest that striatal hyperdopaminergia is not a vulnerability marker for schizophrenia. © 2011 Cambridge University Press.en_HK
dc.languageengen_US
dc.publisherCambridge University Press. The Journal's web site is located at http://journals.cambridge.org/action/displayJournal?jid=PSMen_HK
dc.relation.ispartofPsychological Medicineen_HK
dc.subjectDopamineen_HK
dc.subjectimagingen_HK
dc.subjectschizophreniaen_HK
dc.subjecttwin studyen_HK
dc.titleStriatal dopamine synthesis capacity in twins discordant for schizophreniaen_HK
dc.typeArticleen_HK
dc.identifier.emailToulopoulou, T:timothea@hku.hken_HK
dc.identifier.authorityToulopoulou, T=rp01542en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1017/S0033291711000341en_HK
dc.identifier.pmid21426628-
dc.identifier.scopuseid_2-s2.0-80054923007en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80054923007&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume41en_HK
dc.identifier.issue11en_HK
dc.identifier.spage2331en_HK
dc.identifier.epage2338en_HK
dc.identifier.eissn1469-8978-
dc.identifier.isiWOS:000296246300009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridShotbolt, P=15021251000en_HK
dc.identifier.scopusauthoridStokes, PR=16433059200en_HK
dc.identifier.scopusauthoridOwens, SF=36027261600en_HK
dc.identifier.scopusauthoridToulopoulou, T=8855468700en_HK
dc.identifier.scopusauthoridPicchioni, MM=6507443795en_HK
dc.identifier.scopusauthoridBose, SK=17433582100en_HK
dc.identifier.scopusauthoridMurray, RM=35406239400en_HK
dc.identifier.scopusauthoridHowes, OD=6602176923en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats